These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26427747)
1. Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports. Galip N; Bahceciler N Immunotherapy; 2015; 7(12):1235-9. PubMed ID: 26427747 [TBL] [Abstract][Full Text] [Related]
2. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448 [TBL] [Abstract][Full Text] [Related]
3. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268 [TBL] [Abstract][Full Text] [Related]
4. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma]. Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933 [TBL] [Abstract][Full Text] [Related]
5. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449 [TBL] [Abstract][Full Text] [Related]
7. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. Lee JE; Choi YS; Kim MS; Han DH; Rhee CS; Lee CH; Kim DY Ann Allergy Asthma Immunol; 2011 Jul; 107(1):79-84. PubMed ID: 21704889 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Li P; Li Q; Huang Z; Chen W; Lu Y; Tian M Int Forum Allergy Rhinol; 2014 Oct; 4(10):796-801. PubMed ID: 25145986 [TBL] [Abstract][Full Text] [Related]
10. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy. Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis]. Zhou L; Wang J; Chen Y; Luo R; Tao J; Nie M; Liu B; Li Y Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Oct; 26(20):913-6. PubMed ID: 23272490 [TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864 [TBL] [Abstract][Full Text] [Related]
13. Progress in the development of specific immunotherapies for house dust mite allergies. Moingeon P Expert Rev Vaccines; 2014 Dec; 13(12):1463-73. PubMed ID: 25187166 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Sublingual Immunotherapy with Dermatophagoides farinae Extract in Monosensitized and Polysensitized Patients with Allergic Rhinitis: Clinical Observation and Analysis. Xu CX; Zhang ML; Li BZ; He Y; Zou ZH; Wu QR; Tao AL; Lai H; Sun JL Biomed Res Int; 2015; 2015():187620. PubMed ID: 26000283 [TBL] [Abstract][Full Text] [Related]
15. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Bernstein DI; Bardelas JA; Svanholm Fogh B; Kaur A; Li Z; Nolte H Postgrad Med; 2017 Aug; 129(6):590-597. PubMed ID: 28326906 [TBL] [Abstract][Full Text] [Related]
16. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348 [TBL] [Abstract][Full Text] [Related]
17. Acute systemic reactions to sublingual immunotherapy for house dust mite. Janssens NS; van Ouwerkerk L; Gerth van Wijk R; Karim F Allergy; 2020 Nov; 75(11):2962-2963. PubMed ID: 32449962 [No Abstract] [Full Text] [Related]
18. A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis. Novakova SM; Novakova PI; Yakovliev PH; Staevska MT; Mateva NG; Dimcheva TD; Peichev JL Am J Rhinol Allergy; 2018 May; 32(3):147-152. PubMed ID: 29649893 [TBL] [Abstract][Full Text] [Related]
19. [Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease]. Molina-Sáenz MM; Villa-Arango AM; Cardona-Villa R Rev Alerg Mex; 2017; 64(1):52-65. PubMed ID: 28188713 [TBL] [Abstract][Full Text] [Related]
20. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]